tbuckley/cabot-search huggingface dataset:
Physical Therapy in Mental Disorder
Authors: J. Frank
Journal: BMJ (1946)

<h3>Objective</h3> To compare the daily practice of two emergency departments (ED) in the Netherlands, where systemic inflammatory response syndrome (SIRS) criteria and quick Sequential Organ Failure Assessment (qSOFA) score are used differently as screening tools for culture-positive sepsis. <h3>Design</h3> A prospective cross-sectional multicentre study. <h3>Setting</h3> Two EDs at two European clinical teaching hospitals in the Netherlands. <h3>Participants</h3> 760 patients with suspected infection who met SIRS criteria or had a qualifying qSOFA score who were treated at two EDs in the Netherlands from 1 January to 1 March 2018 were included. <h3>Methods</h3> SIRS criteria and qSOFA score were calculated for each patient. The first hospital treated the patients who met SIRS criteria following the worldwide Surviving Sepsis Campaign protocol. At the second hospital, only patients who met the qualifying qSOFA score received this treatment. Therefore, patients could be divided into five groups: (1) SIRS+, qSOFA−, not treated according to protocol (reference group); (2) SIRS+, qSOFA−, treated according to protocol; (3) SIRS+, qSOFA+, treated according to protocol; (4) SIRS−, qSOFA+, not treated according to protocol; (5) SIRS−, qSOFA+, treated according to protocol. <h3>Primary and secondary outcome measures</h3> To prove culture-positive sepsis was present, cultures were used as the primary outcome. Secondary outcomes were in-hospital mortality and intensive care unit (ICU) admission. <h3>Results</h3> 98.9% met SIRS criteria and 11.7% met qSOFA score. Positive predictive values of SIRS criteria and qSOFA score were 41.2% (95% CI 37.4% to 45.2%) and 48.1% (95% CI 37.4% to 58.9%), respectively. HRs were 0.79 (95% CI 0.40 to 1.56, p=0.500), 3.42 (95% CI 1.82 to 6.44, p&lt;0.001), 18.94 (95% CI 2.48 to 144.89, p=0.005) and 4.97 (95% CI 1.44 to 17.16, p=0.011) for groups 2–5, respectively. <h3>Conclusion</h3> qSOFA score performed as well as SIRS criteria for identifying culture-positive sepsis and performed significantly better for predicting in-hospital mortality and ICU admission. This study shows that SIRS criteria are no longer necessary and recommends qSOFA score as the standard for identifying culture-positive sepsis in the ED. <h3>Trial registration number</h3> NL8315.
Binding and Internalization in Receptor‐Targeted Carriers: The Complex Role of CD44 in the Uptake of Hyaluronic Acid‐Based Nanoparticles (siRNA Delivery)
Authors: Julio M. Rios de la Rosa, Ponpawee Pingrajai, Maria Pelliccia, Alice Spadea, Enrique Lallana, Arianna Gennari, Ian J. Stratford, Walter Rocchia, Annalisa Tirella, Nicola Tirelli
Journal: Advanced Healthcare Materials (2019)

Abstract CD44 is an endocytic hyaluronic acid (HA) receptor, and is overexpressed in many carcinomas. This has encouraged the use of HA to design CD44‐targeting carriers. This paper is about dissecting the mechanistic role of CD44. Here, HA‐decorated nanoparticles are used to deliver siRNA to both tumoral (AsPC‐1, PANC‐1, HT‐29, HCT‐116) and non‐tumoral (fibroblasts, differently polarized THP‐1 macrophages, HUVEC) human cell lines, evaluating the initial binding of the nanoparticles, their internalization rate, and the silencing efficiency (cyclophilin B (PPIB) gene). Tumoral cells internalize faster and experience higher silencing than non‐tumoral cells. This is promising as it suggests that, in a tumor, HA nanocarriers may have limited off‐target effects. More far‐reaching is the inter‐relation between the four parameters of the study: CD44 expression, HA binding on cell surfaces, internalization rate, and silencing efficiency. No correlation is found between binding (an early event) and any of the other parameters, whereas silencing correlates both with speed of the internalization process and CD44 expression. This study confirms on one hand that HA‐based carriers can perform a targeted action, but on the other it suggests that this may not be due to a selective binding event, but rather to a later recognition leading to selective internalization.
Changes in the Multipotent Stromal Mesenchymal Cells from the Bone Marrow of the Patients with Hematological Diseases in Debut and after the Treatment
Authors: Irina N. Shipounova, Nataliya A. Petinati, Nina J. Drize, Aminat A. Magomedova, Ekaterina A. Fastova, Sergey K. Kravchenko, Ekaterina Yu. Chelysheva, Oleg A. Shukhov, Anna G. Turkina, Elena N. Parovichnikova, Valery G. Savchenko
Journal: Blood (2019)
Priming of cytotoxic T-lymphocytes against the novel tumor antigen ErbB3-binding protein-1 (Ebp-1)
Authors: Tanja D. De Gruijl, Saskia J. Santegoets, Marco Schreurs, Marieke Van Ham, Erik Hooijberg, Alfons J. Van Den Eertwegh, Veerle A. Somers, Simon E. Hufton, Hennie R. Hoogenboom, Rik J. Scheper
Journal: Cancer Research (2004)

1274  We recently identified a new colon tumor antigen through the SEREX (SERological identification by recombinant cDNA EXpression cloning) methodology, employing pre- and post-treatment sera from colorectal cancer patients who received autologous whole-cell tumor vaccines. Enhanced post-vaccination reactivity was found for Ebp-1, an ErbB3- and Rb-binding protein, which is involved in oncogenic processes (Xia et al, J. of cell. Physiology, 2001). Immunohistochemical analysis revealed a tumor-specific overexpression of Ebp-1 in colon cancer, further indicating its possible use as a target antigen in the immunotherapy of colorectal cancer. Employing computer algorithms for predictive MHC class I binding affinity and proteosomal cleavage, candidate peptide epitopes were selected. HLA-A2.1 binding affinity was confirmed in a T2-binding assay for two Ebp-1-derived peptides. These peptides were tested for their ability to prime specific cytotoxic T lymphocytes (CTL) in vitro by weekly restimulation of CD8beta+ T cells from healthy donors with peptide-pulsed HLA-A2-matched dendritic cells in the presence of IL-7 and IL-2. We were able to prime CTL against one of these epitopes and after their tetramer-facilitated sorting and expansion, we obtained more than 70% specific bulk cultures. These CTL recognized the naturally processed epitope on the Ebp-1+ breast cancer cell line MCF-7 in an HLA-A2 restricted fashion, as determined through intracellular IFN-gamma staining. We are currently in the process of assessing in vivo priming against these epitopes by monitoring memory CTL in pre- and post-treatment blood samples of vaccinated colon cancer patients.
Subcutaneous Daratumumab Plus Standard Treatment Regimens in Patients with Multiple Myeloma across Lines of Therapy: Pleiades Study Update
Authors: Ajai Chari, Jesús San-Miguel, Helen McCarthy, Kenshi Suzuki, Vania T.M. Hungria, Anna Sureda, Aurore Perrot, Cyrille Hulin, Hila Magen, Shinsuke Iida, Vladimir Maisnar, Lionel Karlin, Ludek Pour, Dolly A. Parasrampuria, Tara Masterson, Michele Kosh, Shiyi Yang, Maria L. Delioukina, Ming Qi, Robin Carson, Cyrille Touzeau
Journal: Blood (2019)
Education and Promotion of MRD Testing within the Multidisciplinary Cancer Care Team for Adults with Acute Lymphoblastic Leukemia in the Community Setting
Authors: Monique D. Dawkins, Firas El Chaer, Leigh Boehmer, Ashkan Emadi, Elias Jabbour, Jeffrey Kendall, Barbara B. Rogers, Sandra Kurtin, Mohamed Hersi, Meredith Barnhart
Journal: Blood (2019)
Pharmacological Increase of Hb-O2 Affinity with a Voxelotor Analog Does Not Decrease Brain Tissue pO2 or Limit O2 Extraction in Brain Tissues of Sickle Cell Mice
Authors: Kobina Dufu, Alfredo Lucas, Cynthia Rodrigues Muller, Alexander T Williams, Xinchun Zhang, Peter Rademacher, Carsten Alt, Donna Oksenberg, Pedro Cabrales
Journal: Blood (2019)
From the authors
Authors: S. Andreas
Journal: European Respiratory Journal (2006)

I would like to thank M. Meysman for raising the interesting aspect of the angiotensin-converting enzyme (ACE) genotype in chronic obstructive pulmonary disease (COPD) patients. I fully agree that the activation of the rennin–angiotensin system is likely to contribute to inflammation, cachexia, pulmonary hypertension and skeletal muscle dysfunction …
Downregulation of Transcription Factor LRF/ZBTB7A Increases Fetal Hemoglobin Expression in β-Thalassemia/Hemoglobin E Erythroid Cells
Authors: Sukanya Chumchuen, Tanapat Pornsukjantra, Pinyaphat Khamphikham, Usanarat Anurathapan, Orapan Sripichai, Duantida Songdej, Suradej Hongeng
Journal: Blood (2019)
Complement C3a Not C4a Activates Osteoclasts By Regulating the PI3K/PDK1/SGK3 Pathway in Patients with Multiple Myeloma
Authors: Rong Fu, Fengjuan Jiang, Hui Liu, Zhaoyun Liu, Siyang Yan, Jin Chen, Zonghong Shao, Qing Shao
Journal: Blood (2019)
Real-World Data on Safety and Efficacy of Venetoclax-Based Regimens in Relapsed/Refractory t[11;14] Multiple Myeloma
Authors: Diana Basali, Rajshekhar Chakraborty, Lisa Rybicki, Nathaniel Rosko, Janice Reed, Mary Ann Karam, Kristen Schlueter, Hayley Dysert, Beth M. Faiman, Kimberly Hamilton, Matt Kalaycio, Jason Valent
Journal: Blood (2019)
Letermovir Prophylaxis Is Effective for Cytomegalovirus Reactivation after Allogeneic Hematopoietic Cell Transplantation: Single Center Real-World Data
Authors: Patrick Derigs, Maria-Luisa Schubert, Paul Schnitzler, Carsten Müller-Tidow, Thomas Luft, Peter Dreger, Michael Schmitt
Journal: Blood (2019)
Diagnostic Testing Patterns and Concordance with World Health Organization (WHO) Criteria for Patients (Pts) with Newly Diagnosed (ND) Myelodysplastic Syndromes (MDS) in the Connect® MDS/AML Registry
Authors: Tracy I. George, Christopher R. Cogle, Guillermo Garcia-Manero, David L. Grinblatt, Rami Komrokji, Michael R. Savona, Bart L. Scott, Mikkael A. Sekeres, David P. Steensma, E. Dawn Flick, Pavel Kiselev, Chrystal U. Louis, Melissa Nifenecker, Arlene S. Swern, Kathryn Foucar
Journal: Blood (2019)
Modelling Single Cell B-Cell Receptor Signaling Reveals Enhanced Activity in Primary CLL Cells Compared to Non-Malignant Cells While Fundamental Network Circuit Topology Remains Stable Even with Novel Therapeutic Inhibitors
Authors: Daniel Mertens, Christine Wolf, Carsten Maus, Michael Persicke, Katharina Filarsky, Hartmut Döhner, Peter Lichter, Thomas Höfer, Stephan Stilgenbauer
Journal: Blood (2019)
TMOD-39. EX-VIVO 3-DIMENSIONAL MODELS OF POST-SURGICAL RESIDUAL DISEASE IN HUMAN GLIOBLASTOMA
Authors: Ola Rominiyi, Katie Myers, Aurelie Vanderlinden, Dawoud Dar, Veejay Bagga, Natividad Gomez-Roman, David Jellinek, Thomas Carroll, Anthony Chalmers, Yahia Al-Tamimi, Spencer Collis
Journal: Neuro-Oncology (2019)

Abstract Translation of novel therapies for glioblastoma from laboratory to clinical trials has relied heavily on cells derived from within patient tumours. However, it is clear from over 40 years of limited improvement in survival rates, that the traditional paradigm of 2-dimensional in-vitro studies using these cells followed by implantation into mouse models poorly predicts the treatment response of glioblastoma cells left behind after surgery in patients. Additionally, recent increases in the number of new therapies requiring pre-clinical evaluation emphasise a need to apply disease models that faithfully and efficiently reproduce biological features of post-surgical residual glioblastoma in patients. Dependent on the anatomical considerations of individual cases, surgical resection occasionally provides an en-bloc specimen (e.g. partial lobectomy), which includes portions of infiltrated brain that would not otherwise be resected. Such specimens provide crucial material to model and understand residual (typically left behind) disease in glioblastoma. Using such specimens, we have developed a pragmatic methodology to liberate glioblastoma stem cells (GSC) from the tumour core and adjacent infiltrated brain to model resected and residual disease, respectively. Imperative considerations include careful patient selection and intraoperative clinical-academic collaboration, with immediate ex-vivo hemi-section and processing of suitable specimens. Initial biological characterisation of our resected and residual models reveals numerous divergent properties including morphological differences and elevated stem cell marker expression in residual models (p=0.0021). Importantly, although GSC within recently derived 2-dimensional residual disease models are frequently too migratory to reliably form discrete colonies, we are able to perform robust clonogenic survival studies using the same GSC within a novel customised 3-dimensional scaffold-based architecture (3.4-fold greater clonogenic potential, p=0.0010). In conclusion, we believe that our models provide a biologically relevant and cost-effective tool to investigate the nuances of residual glioblastoma and assess the potential of therapies to tackle disease normally left behind following surgery in patients.
Acute Chest Syndrome in Children with Sickle Cell Disease in Italy: Results of a National Survey from the Italian Association of Pediatric Hematology Oncology (AIEOP)
Authors: Vania Munaretto, Raffaella Colombatti, Serena Ilaria Tripodi, Corti Paola, Simone Cesaro, Francesco Arcioni, C Piccolo, Tommaso Mina, Marco Zecca, Daniela Cuzzubbo, Maddalena Casale, Giovanni Palazzi, Lucia Notarangelo, Nicoletta Masera, Giovanna Russo, Laura Sainati
Journal: Blood (2019)
Outcomes of Patients with Acute Myeloid Leukemia (AML) with Myelodysplasia Related Changes (AML-MRC) Are Dependent on Diagnostic Criteria and Therapy
Authors: Guillermo Montalban Bravo, Rashmi Kanagal-Shamanna, Koji Sasaki, Farhad Ravandi, Jorge E. Cortes, Naval G. Daver, Koichi Takahashi, Courtney D. DiNardo, Elias Jabbour, Gautam M. Borthakur, Kiran Naqvi, Marina Y Konopleva, Sherry A. Pierce, Carlos E. Bueso-Ramos, Keyur P. Patel, Hagop M. Kantarjian, Guillermo Garcia-Manero, Tapan M. Kadia
Journal: Blood (2019)
Phase II Study of Blinatumomab in Patients with B-Cell Acute Lymphoblastic Leukemia (B-ALL) with Positive Measurable Residual Disease (MRD)
Authors: Guillaume Richard-Carpentier, Hagop M. Kantarjian, Jeffrey L. Jorgensen, Sa A Wang, Joseph D. Khoury, Farhad Ravandi, Nicholas J. Short, Rita Khouri, Koichi Takahashi, Maro Ohanian, Gautam M. Borthakur, Marina Y Konopleva, Naval G. Daver, Zeev E. Estrov, Yesid Alvarado, Nitin Jain, Tapan M. Kadia, Guillermo Garcia-Manero, Michelle Velasquez, Patrice Nasnas, Susan O'Brien, Elias Jabbour
Journal: Blood (2019)
Do Salaried Physician Specialists Provide Less Care to Patients With Chronic Disease?
Authors: Samaya J. Anumudu, Ahmed A. Awan, Kevin F. Erickson
Journal: JAMA Network Open (2019)

Amity E. Quinn, PhD; Brenda R. Hemmelgarn, MD, PhD; Marcello Tonelli, MD, SM; Kerry A. McBrien, MD, MPH; Alun Edwards, MB, BChir; Peter Senior, MBBS, PhD; Peter Faris, PhD; Flora Au, MA; Zhihai Ma, MSc; Robert G. Weaver, MSc; Braden J. Manns, MD, MSc
Large‐Scale Production of LGR5‐Positive Bipotential Human Liver Stem Cells
Authors: Kerstin Schneeberger, Natalia Sánchez‐Romero, Shicheng Ye, Frank G. van Steenbeek, Loes A. Oosterhoff, Iris Pla Palacin, Chen Chen, Monique E. van Wolferen, Gilles van Tienderen, Ruby Lieshout, Haaike Colemonts‐Vroninks, Imre Schene, Ruurdtje Hoekstra, Monique M.A. Verstegen, Luc J.W. van der Laan, Louis C. Penning, Sabine A. Fuchs, Hans Clevers, Joery De Kock, Pedro M. Baptista, Bart Spee
Journal: Hepatology (2019)

Background and Aims The gap between patients on transplant waiting lists and available donor organs is steadily increasing. Human organoids derived from leucine‐rich repeat‐containing G protein‐coupled receptor 5 (LGR5)–positive adult stem cells represent an exciting new cell source for liver regeneration; however, culturing large numbers of organoids with current protocols is tedious and the level of hepatic differentiation is limited. Approach and Results Here, we established a method for the expansion of large quantities of human liver organoids in spinner flasks. Due to improved oxygenation in the spinner flasks, organoids rapidly proliferated and reached an average 40‐fold cell expansion after 2 weeks, compared with 6‐fold expansion in static cultures. The organoids repopulated decellularized liver discs and formed liver‐like tissue. After differentiation in spinner flasks, mature hepatocyte markers were highly up‐regulated compared with static organoid cultures, and cytochrome p450 activity reached levels equivalent to hepatocytes. Conclusions We established a highly efficient method for culturing large numbers of LGR5‐positive stem cells in the form of organoids, which paves the way for the application of organoids for tissue engineering and liver transplantation.
Durvalumab (Anti PD-L1) As Monotherapy or in Combination Therapy for Relapsed/Refractory (r/r) Diffuse Large B-Cell Lymphoma (DLBCL) and Follicular Lymphoma (FL): A Subgroup Analysis from the Phase 1/2 Fusion NHL-001 Global Multicenter Trial
Authors: Carla Casulo, Armando Santoro, Kiyoshi Ando, Steven Le Gouill, Jia Ruan, John Radford, Luca Arcaini, Antonello Pinto, Reda Bouabdallah, Koji Izutsu, Simon Rule, Javier Munoz, Marie-Laure Casadebaig, Brian Fox, Nils Rettby, Justine Dell'Aringa, Richard Delarue, Kathryn Newhall, Myron Czuczman, Guillaume Cartron
Journal: Blood (2019)
Comparison of real-world treatment patterns among patients with psoriasis prescribed ixekizumab or secukinumab
Authors: Andrew Blauvelt, Nianwen Shi, Russel Burge, William N. Malatestinic, Chen-Yen Lin, Carolyn R. Lew, Nicole M. Zimmerman, Orin M. Goldblum, Baojin Zhu, Mwangi J. Murage
Journal: Journal of the American Academy of Dermatology (2019)
Pdox Models Empower Preclinical Drug Evaluation and Mechanistic Studies Via Faithful Recapitulation of the Pathology, Complex Heterogeneity, Genetic-Transcriptomic Landscape, and Therapeutic Response of Mantle Cell Lymphoma
Authors: Changying Jiang, Shaojun Zhang, Shengjian Huang, Yang Liu, Rongjia Zhang, Angela Leeming, Joseph Mitchell McIntosh, William Lee, Krystle Nomie, Linghua Wang, Michael L. Wang
Journal: Blood (2019)
Effect of Face-to-Face vs Virtual Reality Training on Cardiopulmonary Resuscitation Quality
Authors: Joris Nas, Jos Thannhauser, Priya Vart, Robert-Jan van Geuns, Hella E. C. Muijsers, Jan-Quinten Mol, Goaris W. A. Aarts, Lara S. F. Konijnenberg, D. H. Frank Gommans, Sandra G. A. M. Ahoud-Schoenmakers, Jacqueline L. Vos, Niels van Royen, Judith L. Bonnes, Marc A. Brouwer
Journal: JAMA Cardiology (2019)

Bystander cardiopulmonary resuscitation (CPR) is crucial for survival after cardiac arrest but not performed in most cases. New, low-cost, and easily accessible training methods, such as virtual reality (VR), may reach broader target populations, but data on achieved CPR skills are lacking.To compare CPR quality between VR and face-to-face CPR training.Randomized noninferiority trial with a prospective randomized open blinded end point design. Participants were adult attendees from the science section of the Lowlands Music Festival (August 16 to 18, 2019) in the Netherlands. Analysis began September 2019.Two standardized 20-minute protocols on CPR and automated external defibrillator use: instructor-led face-to-face training or VR training using a smartphone app endorsed by the Resuscitation Council (United Kingdom).During a standardized CPR scenario following the training, we assessed the primary outcome CPR quality, measured as chest compression depth and rate using CPR manikins. Overall CPR performance was assessed by examiners, blinded for study groups, using a European Resuscitation Council-endorsed checklist (maximum score, 13). Additional secondary outcomes were chest compression fraction, proportions of participants with mean depth (50 mm-60 mm) or rate (100 min-1-120 min-1) within guideline ranges, and proportions compressions with full release.A total of 381 participants were randomized: 216 women (57%); median (interquartile range [IQR]) age, 26 (22-31) years. The VR app (n = 190 [49.9%]) was inferior to face-to-face training (n = 191 [50.1%]) for chest compression depth (mean [SD], VR: 49 [10] mm vs face to face: 57 [5] mm; mean [95% CI] difference, -8 [-9 to -6] mm), and noninferior for chest compression rate (mean [SD]: VR: 114 [12] min-1 vs face to face: 109 [12] min-1; mean [95% CI] difference, 6 [3 to 8] min-1). The VR group had lower overall CPR performance scores (median [IQR], 10 [8-12] vs 12 [12-13]; P < .001). Chest compression fraction (median [IQR], 61% [52%-66%] vs 67% [62%-71%]; P < .001) and proportions of participants fulfilling depth (51% [n = 89] vs 75% [n = 133], P < .001) and rate (50% [n = 87] vs 63% [n = 111], P = .01) requirements were also lower in the VR group. The proportion of compressions with full release was higher in the VR group (median [IQR], 98% [59%-100%] vs 88% [55%-99%]; P = .002).In this randomized noninferiority trial, VR training resulted in comparable chest compression rate but inferior compression depth compared with face-to-face training. Given the potential of VR training to reach a larger target population, further development is needed to achieve the compression depth and overall CPR skills acquired by face-to-face training.ClinicalTrials.gov identifier: NCT04013633.
Effects of Interatrial Shunt on Pulmonary Vascular Function in Heart Failure With Preserved Ejection Fraction
Authors: Masaru Obokata, Yogesh N.V. Reddy, Sanjiv J. Shah, David M. Kaye, Finn Gustafsson, Gerd Hasenfuβ, Elke Hoendermis, Sheldon E. Litwin, Jan Komtebedde, Carolyn Lam, Daniel Burkhoff, Barry A. Borlaug
Journal: Journal of the American College of Cardiology (2019)
Human autologous iPSC–derived dopaminergic progenitors restore motor function in Parkinson’s disease models
Authors: Bin Song, Young Cha, Sanghyeok Ko, Jeha Jeon, Nayeon Lee, Hyemyung Seo, Kyung-Joon Park, In-Hee Lee, Claudia Lopes, Melissa Feitosa, María José Luna, Jin Hyuk Jung, Jisun Kim, Dabin Hwang, Bruce M. Cohen, Martin H. Teicher, Pierre Leblanc, Bob S. Carter, Jeffrey H. Kordower, Vadim Y. Bolshakov, Sek Won Kong, Jeffrey S. Schweitzer, Kwang-Soo Kim
Journal: Journal of Clinical Investigation (2019)

Parkinson's disease (PD) is a neurodegenerative disorder associated with loss of striatal dopamine, secondary to degeneration of midbrain dopamine (mDA) neurons in the substantia nigra, rendering cell transplantation a promising therapeutic strategy. To establish human induced pluripotent stem cell–based (hiPSC-based) autologous cell therapy, we report a platform of core techniques for the production of mDA progenitors as a safe and effective therapeutic product. First, by combining metabolism-regulating microRNAs with reprogramming factors, we developed a method to more efficiently generate clinical-grade iPSCs, as evidenced by genomic integrity and unbiased pluripotent potential. Second, we established a "spotting"-based in vitro differentiation methodology to generate functional and healthy mDA cells in a scalable manner. Third, we developed a chemical method that safely eliminates undifferentiated cells from the final product. Dopaminergic cells thus express high levels of characteristic mDA markers, produce and secrete dopamine, and exhibit electrophysiological features typical of mDA cells. Transplantation of these cells into rodent models of PD robustly restores motor function and reinnervates host brain, while showing no evidence of tumor formation or redistribution of the implanted cells. We propose that this platform is suitable for the successful implementation of human personalized autologous cell therapy for PD.
Post-Transplant Cyclophosphamide after Matched Sibling, Unrelated and Haploidentical Donor Transplants in Patients with Acute Myeloid Leukemia, a Comparative Study of the ALWP EBMT
Authors: Jaime Sanz, Jaques-Emmanuel Galimard, Boris V Afanasyev, Emanuele Angelucci, Fabio Ciceri, Didier Blaise, Jan J Cornelissen, Ellen Meijer, José Luis Díez-Martín, Yener Koc, Montserrat Rovira, Luca Castagna, Bipin N. Savani, Annalisa Ruggeri, Mohamad Mohty, Arnon Nagler
Journal: Blood (2019)